Market capitalization | €13.53b |
Enterprise Value | €22.86b |
P/E (TTM) P/E ratio | 22.03 |
EV/FCF (TTM) EV/FCF | 13.60 |
EV/Sales (TTM) EV/Sales | 1.17 |
P/S ratio (TTM) P/S ratio | 0.69 |
P/B ratio (TTM) P/B ratio | 0.95 |
Dividend yield | 3.10% |
Last dividend (FY24) | €1.44 |
Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.
22 Analysts have issued a Fresenius Medical Care forecast:
22 Analysts have issued a Fresenius Medical Care forecast:
Mar '25 |
+/-
%
|
||
Revenue | 19,493 19,493 |
0%
0%
|
|
Gross Profit | 4,767 4,767 |
4%
4%
|
|
EBITDA | 3,023 3,023 |
3%
3%
|
EBIT (Operating Income) EBIT | 1,398 1,398 |
9%
9%
|
Net Profit | 618 618 |
28%
28%
|
In millions EUR.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Fresenius Medical Care AG & Co. KGaA engages in the provision of products and services for patients with chronic kidney failure. It also develop and manufacture a variety of health care products, which includes dialysis and non-dialysis products. The company was founded on August 5, 1996 and is headquartered in Bad Homburg, Germany.
Head office | Germany |
CEO | Helen Giza |
Employees | 111,513 |
Founded | 1996 |
Website | www.freseniusmedicalcare.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.